跳至主要内容
临床试验/NCT03951714
NCT03951714已完成不适用

12-wks Randomised Controlled Trial to Explore the Effect of a Smartphone App. Connected to an Add-on Device System Fitted on pMDI Inhaler on Adherence to Medications Intake and Clinical Outcomes in Difficult-to-treat Asthmatic Patients

Chiesi Farmaceutici S.p.A.2 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2019年8月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
160
试验地点
2
主要终点
Change from Baseline in adherence rate to entire treatment period

研究概览

简要总结

The purpose of this Study is to assess the effect of a smartphone application connected to an add-on device system fitted on Pressured Metered Dose Inhaler (PMDI) on adherence to take medications as prescribed and clinical outcomes in difficult-to-treat asthmatic patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient's written informed consent obtained prior to any study-related procedures
  • Male or female patient aged 18 years and above
  • Patient with established diagnosis of asthma for at least 6 months
  • Patient on maintenance therapy (Fixed dose combination ICS/LABA) with high dose of ICS
  • Patient with ACT score <20 at screening and at randomization
  • Non- or ex-smoker who smoked ≤ 10 Pack-years prior to screening
  • Patient must have their own Android® or iPhone operating system (IOS) smartphone
  • Ability to use the pMDI device correctly

排除标准

  • Patient with an asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 to 3 month prior to screening
  • Patient with a history of near-fatal asthma
  • Clinically relevant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, psychiatric or any other disorder that would put the safety of the subject at risk through participation, or which would affect the analysis
  • Patient not able to be compliant with the study requirements.
  • Patient with a BMI > 40
  • Patient working on night shifts
  • Patient participating in the clinical phase of an interventional trial or have done so within the last 30 days prior to screening.
  • Patient who has an already planned major surgery or hospitalization
  • Female patient who is pregnant or lactating or who plans to become pregnant in the next 4 months.
  • Patient with a history of hypersensitivity to any of the components of Foster pMDI

结局指标

主要结局

Change from Baseline in adherence rate to entire treatment period

时间窗: From baseline to end of participation (up to 3 months)

Adherence Rate of doses correctly taken twice daily

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验